Janssen Pharm. — Medicare Part D spending
Rank #8 by attributed Part D spend · 20 tracked drugs · CMS data year 2023
About $9,563,155,777 of Medicare Part D spending in 2023 is attributed to Janssen Pharm. across the 20 of its drugs tracked here, ranking it #8 among manufacturers on this site. Its biggest Part D drug is Xarelto at $6,309,246,823. Attribution uses the CMS manufacturer lists and is indicative, not definitive. These are aggregate program figures, not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Janssen Pharm. drugs in Medicare Part D (2023)
| Brand | Generic | Total spend | Per dosage unit | Beneficiaries | Spend rank |
|---|---|---|---|---|---|
| <a href="/drug/xarelto-rivaroxaban/">Xarelto</a> | Rivaroxaban | $6,309,246,823 | $18.23 | 1,324,165 | #5 |
| <a href="/drug/invega-sustenna-paliperidone-palmitate/">Invega Sustenna</a> | Paliperidone Palmitate | $1,821,418,393 | $2,343.53 | 70,988 | #26 |
| <a href="/drug/invega-trinza-paliperidone-palmitate/">Invega Trinza</a> | Paliperidone Palmitate | $529,817,416 | $3,995.87 | 18,591 | #101 |
| <a href="/drug/invokana-canagliflozin/">Invokana</a> | Canagliflozin | $357,419,494 | $20.48 | 69,576 | #152 |
| <a href="/drug/risperdal-consta-risperidone-microspheres/">Risperdal Consta</a> | Risperidone Microspheres | $181,758,052 | $968.00 | 11,151 | #246 |
| Spravato | Esketamine HCl | $80,470,297 | $382.22 | 3,884 | #457 |
| Invega Hafyera | Paliperidone Palmitate | $79,118,112 | $4,101.51 | 2,765 | #460 |
| Elmiron | Pentosan Polysulfate Sodium | $55,269,822 | $11.27 | 9,394 | #583 |
| Topamax | Topiramate | $47,505,378 | $17.07 | 3,265 | #633 |
| Zytiga | Abiraterone Acetate | $33,242,472 | $145.80 | 562 | #751 |
| Invokamet | Canagliflozin/Metformin HCl | $22,206,495 | $10.28 | 4,565 | #923 |
| Concerta | Methylphenidate HCl | $14,681,764 | $14.16 | 6,062 | #1081 |
| Invokamet XR | Canagliflozin/Metformin HCl | $13,108,387 | $10.25 | 3,060 | #1126 |
| Ponvory | Ponesimod | $8,307,094 | $326.24 | 99 | #1311 |
| Invega | Paliperidone | $5,169,576 | $14.65 | 2,964 | #1481 |
| Risperdal | Risperidone | $4,170,926 | $7.82 | 957 | #1561 |
| Sporanox | Itraconazole | $196,502 | $13.25 | 25 | #2635 |
| Ditropan XL | Oxybutynin Chloride | $41,908 | $6.76 | 39 | #3013 |
| Haldol Decanoate 50 | Haloperidol Decanoate | $5,317 | $71.85 | 13 | #3370 |
| Haldol Decanoate 100 | Haloperidol Decanoate | $1,550 | $86.13 | 12 | #3498 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Frequently asked questions
How much Medicare Part D spending does Janssen Pharm. get?
In 2023, about $9,563,155,777 of Medicare Part D spending is attributed to Janssen Pharm. across the 20 of its drugs tracked here. Its biggest is Xarelto at $6,309,246,823. This is gross program spending, not what patients pay. Source: CMS, data year 2023.
What is Janssen Pharm.'s top Medicare Part D drug?
Among the drugs tracked here, Janssen Pharm.'s highest Part D spending in 2023 is Xarelto at $6,309,246,823 (national rank #5 by total spend).
Is manufacturer attribution exact?
No. CMS may list multiple manufacturers per drug, and labeler relationships change over time. We attribute each drug to its primary listed manufacturer, so these rollups are indicative rather than definitive. Always check the underlying CMS file for a specific drug.
Keep exploring
Data: CMS Medicare Part D Spending by Drug (data year 2023), U.S. public domain. Aggregate program spending, not prices. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-21